Untangling the ErbB signalling network

When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signalling pathways, culminating in responses ranging from cell division to death, motility to adhesion. The network is often dysregulated in cancer and lends credence to the mantra that molecular understanding yields clinical benefit: over 25,000 women with breast cancer have now been treated with trastuzumab (Herceptin®), a recombinant antibody designed to block the receptor ErbB2. Likewise, small-molecule enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clinical testing. What can this pathway teach us about translating basic science into clinical use?

[1]  G. Carpenter,et al.  Human epidermal growth factor: isolation and chemical and biological properties. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Dickson,et al.  Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. , 1987, Endocrine reviews.

[3]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[4]  V. Brown,et al.  Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts , 1989, Cell.

[5]  P. Sternberg,et al.  Multiple functions of let-23, a Caenorhabditis elegans receptor tyrosine kinase gene required for vulval induction. , 1991, Genetics.

[6]  Acknowledgements , 1992, Experimental Gerontology.

[7]  V. Gorgoulis,et al.  Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas. , 1992, Anticancer research.

[8]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. McFadden,et al.  Transforming growth factor alpha, Shope fibroma growth factor, and vaccinia growth factor can replace myxoma growth factor in the induction of myxomatosis in rabbits. , 1993, Virology.

[10]  David C. Lee,et al.  TGFα deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice , 1993, Cell.

[11]  H. Friess,et al.  Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. , 1993, Anticancer research.

[12]  J. Brugge.  New intracellular targets for therapeutic drug design. , 1993, Science.

[13]  J. E. Gee,et al.  Triplex formation inhibits HER-2/neu transcription in vitro. , 1993, The Journal of clinical investigation.

[14]  A. Bernstein,et al.  Oncogenes in head and neck cancer , 1993, The Laryngoscope.

[15]  E. Nice,et al.  Mice with a null mutation of the TGFα gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation , 1993, Cell.

[16]  G. Carpenter,et al.  The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. , 1993, Oncogene.

[17]  G. Natoli,et al.  Trans-activation of epidermal growth factor receptor gene by the hepatitis B virus X-gene product. , 1993, Virology.

[18]  L. Cantley,et al.  Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S Lay,et al.  Computer simulated evolution of a network of cell-signaling molecules. , 1994, Biophysical journal.

[20]  N. Hynes,et al.  Intracellular expression of single chain antibodies reverts ErbB-2 transformation. , 1994, The Journal of biological chemistry.

[21]  W. Dougall,et al.  Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation. , 1994, Oncogene.

[22]  H. Modjtahedi,et al.  The receptor for EGF and its ligands - expression, prognostic value and target for therapy in cancer (review). , 1994, International journal of oncology.

[23]  M. Kraus,et al.  Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members , 1994, Molecular and cellular biology.

[24]  Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members , 1994 .

[25]  M. Fernö,et al.  ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. , 1994, Cancer letters.

[26]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[27]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[28]  T. van Raaij,et al.  The cellular response to neuregulins is governed by complex interactions of the erbB receptor family , 1995, Molecular and cellular biology.

[29]  D. McCance,et al.  The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes , 1995, Journal of virology.

[30]  B. Shilo,et al.  Secreted Spitz triggers the DER signaling pathway and is a limiting component in embryonic ventral ectoderm determination. , 1995, Genes & development.

[31]  R. Derynck,et al.  Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor , 1995, Nature.

[32]  S. Keyse,et al.  Tyrosine kinase inhibition: an approach to drug development. , 1995, Human & experimental toxicology.

[33]  M. Sliwkowski,et al.  HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. , 1995, Oncogene.

[34]  M. Kraus,et al.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.

[35]  M. Freeman,et al.  Inhibition of Drosophila EGF receptor activation by the secreted protein Argos , 1995, Nature.

[36]  A. Ullrich,et al.  Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. , 1995, The EMBO journal.

[37]  J. Biegel,et al.  Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. , 1995, Cancer research.

[38]  K. Herrup,et al.  Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.

[39]  Y. Yoshihama,et al.  Prognostic significance of ERRB3 overexpression in oral squamous cell carcinoma , 1995 .

[40]  Y. Yoshihama,et al.  Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma. , 1995, Cancer letters.

[41]  W. Miller,et al.  The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor , 1995, Journal of virology.

[42]  M. Sliwkowski,et al.  The influence of heregulins on human Schwann cell proliferation , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[43]  C. Cordon-Cardo,et al.  Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  M. Caruthers,et al.  Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Yamashita,et al.  Localization of heparin-binding epidermal growth factor-like growth factor in human coronary arteries. Possible roles of HB-EGF in the formation of coronary atherosclerosis. , 1996, Circulation.

[46]  N. Maihle,et al.  Ligand-independent dimerization of oncogenic v-erbB products involves covalent interactions , 1996, Journal of virology.

[47]  G. Carpenter,et al.  All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*) , 1996, The Journal of Biological Chemistry.

[48]  S. Lev,et al.  A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation , 1996, Nature.

[49]  L. Theill,et al.  Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Y. Yarden,et al.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.

[51]  Y. Yarden,et al.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.

[52]  D Tripathy,et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  P. Leder,et al.  NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. , 1996, Oncogene.

[54]  L. Cantley,et al.  p120 Is a Cytosolic Adapter Protein That Associates with Phosphoinositide 3-Kinase in Response to Epidermal Growth Factor in PC12 and Other Cells (*) , 1996, The Journal of Biological Chemistry.

[55]  M. Rubin,et al.  Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. , 1996, Oncogene.

[56]  A. Bianco,et al.  c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  G. Frantz,et al.  ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. , 1997, Development.

[58]  M. Berens,et al.  The Role of Cultured Schwann Cell Grafts in the Repair of Gaps within the Peripheral Nervous System of Primates , 1997, Experimental Neurology.

[59]  Kohjiro Ueki,et al.  Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone , 1997, Nature.

[60]  M. Melhem,et al.  Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. , 1997, The cancer journal from Scientific American.

[61]  D. Curiel,et al.  A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients. , 1997, Human gene therapy.

[62]  M. Eisenstein,et al.  Bivalence of EGF‐like ligands drives the ErbB signaling network , 1997, The EMBO journal.

[63]  Joe Y. Chang,et al.  The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer* , 1997, Oncogene.

[64]  M. Cheever,et al.  HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. , 1997, Advances in cancer research.

[65]  Yosef Yarden,et al.  Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis , 1997, Neuron.

[66]  H. Wiley,et al.  Structural Aspects of the Epidermal Growth Factor Receptor Required for Transmodulation of erbB-2/neu* , 1997, The Journal of Biological Chemistry.

[67]  D. Riethmacher,et al.  Severe neuropathies in mice with targeted mutations in the ErbB3 receptor , 1997, Nature.

[68]  Michael Sasner,et al.  Neuregulin-β induces expression of an NMDA-receptor subunit , 1997, Nature.

[69]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  G. Fischbach,et al.  ARIA: a neuromuscular junction neuregulin. , 1997, Annual review of neuroscience.

[71]  R H Perry,et al.  Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. , 1997, Cancer research.

[72]  R. Lefkowitz,et al.  Gbetagamma subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation. , 1997, The Journal of biological chemistry.

[73]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[74]  A. Ullrich,et al.  Signal characteristics of G protein‐transactivated EGF receptor , 1997, The EMBO journal.

[75]  W. Denny,et al.  Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[76]  R. Graham,et al.  Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[77]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.

[78]  Monilola A. Olayioye,et al.  ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner , 1998, Molecular and Cellular Biology.

[79]  E. Wagner,et al.  A strain‐independent postnatal neurodegeneration in mice lacking the EGF receptor , 1998, The EMBO journal.

[80]  B. Geiger,et al.  Alternative Intracellular Routing of ErbB Receptors May Determine Signaling Potency* , 1998, The Journal of Biological Chemistry.

[81]  A. Lenferink,et al.  Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers , 1998, The EMBO journal.

[82]  Z. Kam,et al.  c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. , 1998, Genes & development.

[83]  S. Ménard,et al.  Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation , 1998, Oncogene.

[84]  H. Kung,et al.  Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells , 1998, Nature.

[85]  D. Riethmacher,et al.  The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. , 1998, Genes & development.

[86]  L. Schaeffer,et al.  Implication of a multisubunit Ets related transcription factor in synaptic expression of the nicotinic acetylcholine receptor , 1998, Journal of Physiology-Paris.

[87]  D. Bigner,et al.  The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. , 1998, Journal of neurovirology.

[88]  T. Volk.  Singling out Drosophila tendon cells: a dialogue between two distinct cell types. , 1999, Trends in genetics : TIG.

[89]  M. Caron,et al.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.

[90]  Y. Yarden,et al.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[91]  A. Ullrich,et al.  EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF , 1999, Nature.

[92]  G. Carpenter.  Employment of the Epidermal Growth Factor Receptor in Growth Factor–Independent Signaling Pathways , 1999, The Journal of cell biology.

[93]  J. Fletcher,et al.  The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. , 1999, Seminars in cancer biology.

[94]  M. Sliwkowski,et al.  Binding specificities and affinities of egf domains for ErbB receptors , 1999, FEBS letters.

[95]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  D. Johnston,et al.  Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[97]  M. Klagsbrun,et al.  Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase , 1999, Oncogene.

[98]  D. Lauffenburger,et al.  Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[99]  M. Sliwkowski,et al.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.

[100]  A. Wells.  EGF receptor. , 1999, The international journal of biochemistry & cell biology.

[101]  J. Brugge,et al.  Controlled Dimerization of ErbB Receptors Provides Evidence for Differential Signaling by Homo- and Heterodimers , 1999, Molecular and Cellular Biology.

[102]  R. Pinkas-Kramarski,et al.  ErbB‐4 Activation Promotes Neurite Outgrowth in PC12 Cells , 2000, Journal of neurochemistry.

[103]  E. Liu,et al.  HER2 as a predictor of therapeutic response in breast cancer. , 2000, Breast disease.

[104]  B. Klein,et al.  Inhibitors of tyrosine kinases in the treatment of psoriasis. , 2000, Current pharmaceutical design.

[105]  A. Friedman,et al.  Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[106]  M. Lemmon,et al.  Extracellular domains drive homo‐ but not hetero‐dimerization of erbB receptors , 2000, The EMBO journal.

[107]  I. Ellis,et al.  c-erbB-4 protein expression in human breast cancer , 2000, British Journal of Cancer.

[108]  A. Aigner,et al.  ERbB‐2 expression is rate‐limiting for epidermal growth factor–mediated stimulation of ovarian cancer cell proliferation , 2000, International journal of cancer.

[109]  M. Klagsbrun,et al.  A Natural ErbB4 Isoform That Does Not Activate Phosphoinositide 3-Kinase Mediates Proliferation but Not Survival or Chemotaxis* , 2000, The Journal of Biological Chemistry.

[110]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[111]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[112]  J. Abraham,et al.  Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. , 2000, Circulation research.

[113]  R. Landgraf,et al.  Heregulin reverses the oligomerization of HER3. , 2000, Biochemistry.

[114]  M. Sliwkowski,et al.  Neuregulin-1 and human epidermal growth factor receptors 2 and 3 play a role in human lung development in vitro. , 2000, American journal of respiratory cell and molecular biology.

[115]  B. Geiger,et al.  Molecular requirements for the effect of neuregulin on cell spreading, motility and colony organization , 2000, Oncogene.

[116]  D. Birnbaum,et al.  ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor , 2000, Nature Cell Biology.